Press release content from Globe Newswire. The AP news staff was not involved in its creation. Medigus: Polyrizon Commenced a Pre-Clinical Study Testing Several Formulations of its Bio-Gel ... Medigus LtdApril 12, 2021 GMT OMER, Israel, April 12, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions and innovative internet technologies, today announced that Polyrizon Ltd. (which Medigus owns 33.24% of its share capital), a private company engaged in developing highly differentiated biological gels for the purpose of protecting patients against biological threats and external pathogens, commenced a pre-clinical trial to examine its bio-gel efficacy to protect against coronavirus infection.